Cargando…
Nanotechnological engineering of extracellular vesicles for the development of actively targeted hybrid nanodevices
BACKGROUND: We propose an efficient method to modify B-cell derived EVs by loading them with a nanotherapeutic stimuli-responsive cargo and equipping them with antibodies for efficient targeting of lymphoma cells. RESULTS: The post-isolation engineering of the EVs is accomplished by a freeze–thaw me...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107671/ https://www.ncbi.nlm.nih.gov/pubmed/35568919 http://dx.doi.org/10.1186/s13578-022-00784-9 |
_version_ | 1784708533725429760 |
---|---|
author | Dumontel, Bianca Susa, Francesca Limongi, Tania Vighetto, Veronica Debellis, Doriana Canta, Marta Cauda, Valentina |
author_facet | Dumontel, Bianca Susa, Francesca Limongi, Tania Vighetto, Veronica Debellis, Doriana Canta, Marta Cauda, Valentina |
author_sort | Dumontel, Bianca |
collection | PubMed |
description | BACKGROUND: We propose an efficient method to modify B-cell derived EVs by loading them with a nanotherapeutic stimuli-responsive cargo and equipping them with antibodies for efficient targeting of lymphoma cells. RESULTS: The post-isolation engineering of the EVs is accomplished by a freeze–thaw method to load therapeutically-active zinc oxide nanocrystals (ZnO NCs), obtaining the so-called TrojanNanoHorse (TNH) to recall the biomimetism and cytotoxic potential of this novel nanoconstruct. TNHs are further modified at their surface with anti-CD20 monoclonal antibodies (TNH(CD20)) achieving specific targeting against lymphoid cancer cell line. The in vitro characterization is carried out on CD20+ lymphoid Daudi cell line, CD20-negative cancerous myeloid cells (HL60) and the healthy counterpart (B lymphocytes). The TNH shows nanosized structure, high colloidal stability, even over time, and good hemocompatibility. The in vitro characterization shows the high biocompatibility, targeting specificity and cytotoxic capability. Importantly, the selectivity of TNH(CD20) demonstrates significantly higher interaction towards the target lymphoid Daudi cell line compared to the CD20-negative cancerous myeloid cells (HL60) and the healthy counterpart (lymphocytes). An enhanced cytotoxicity directed against Daudi cancer cells is demonstrated after the TNH(CD20) activation with high-energy ultrasound shock-waves (SW). CONCLUSION: This work demonstrates the efficient re-engineering of EVs, derived from healthy cells, with inorganic nanoparticles and monoclonal antibodies. The obtained hybrid nanoconstructs can be on-demand activated by an external stimulation, here acoustic pressure waves, to exploit a cytotoxic effect conveyed by the ZnO NCs cargo against selected cancer cells. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13578-022-00784-9. |
format | Online Article Text |
id | pubmed-9107671 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-91076712022-05-16 Nanotechnological engineering of extracellular vesicles for the development of actively targeted hybrid nanodevices Dumontel, Bianca Susa, Francesca Limongi, Tania Vighetto, Veronica Debellis, Doriana Canta, Marta Cauda, Valentina Cell Biosci Research BACKGROUND: We propose an efficient method to modify B-cell derived EVs by loading them with a nanotherapeutic stimuli-responsive cargo and equipping them with antibodies for efficient targeting of lymphoma cells. RESULTS: The post-isolation engineering of the EVs is accomplished by a freeze–thaw method to load therapeutically-active zinc oxide nanocrystals (ZnO NCs), obtaining the so-called TrojanNanoHorse (TNH) to recall the biomimetism and cytotoxic potential of this novel nanoconstruct. TNHs are further modified at their surface with anti-CD20 monoclonal antibodies (TNH(CD20)) achieving specific targeting against lymphoid cancer cell line. The in vitro characterization is carried out on CD20+ lymphoid Daudi cell line, CD20-negative cancerous myeloid cells (HL60) and the healthy counterpart (B lymphocytes). The TNH shows nanosized structure, high colloidal stability, even over time, and good hemocompatibility. The in vitro characterization shows the high biocompatibility, targeting specificity and cytotoxic capability. Importantly, the selectivity of TNH(CD20) demonstrates significantly higher interaction towards the target lymphoid Daudi cell line compared to the CD20-negative cancerous myeloid cells (HL60) and the healthy counterpart (lymphocytes). An enhanced cytotoxicity directed against Daudi cancer cells is demonstrated after the TNH(CD20) activation with high-energy ultrasound shock-waves (SW). CONCLUSION: This work demonstrates the efficient re-engineering of EVs, derived from healthy cells, with inorganic nanoparticles and monoclonal antibodies. The obtained hybrid nanoconstructs can be on-demand activated by an external stimulation, here acoustic pressure waves, to exploit a cytotoxic effect conveyed by the ZnO NCs cargo against selected cancer cells. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13578-022-00784-9. BioMed Central 2022-05-14 /pmc/articles/PMC9107671/ /pubmed/35568919 http://dx.doi.org/10.1186/s13578-022-00784-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Dumontel, Bianca Susa, Francesca Limongi, Tania Vighetto, Veronica Debellis, Doriana Canta, Marta Cauda, Valentina Nanotechnological engineering of extracellular vesicles for the development of actively targeted hybrid nanodevices |
title | Nanotechnological engineering of extracellular vesicles for the development of actively targeted hybrid nanodevices |
title_full | Nanotechnological engineering of extracellular vesicles for the development of actively targeted hybrid nanodevices |
title_fullStr | Nanotechnological engineering of extracellular vesicles for the development of actively targeted hybrid nanodevices |
title_full_unstemmed | Nanotechnological engineering of extracellular vesicles for the development of actively targeted hybrid nanodevices |
title_short | Nanotechnological engineering of extracellular vesicles for the development of actively targeted hybrid nanodevices |
title_sort | nanotechnological engineering of extracellular vesicles for the development of actively targeted hybrid nanodevices |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107671/ https://www.ncbi.nlm.nih.gov/pubmed/35568919 http://dx.doi.org/10.1186/s13578-022-00784-9 |
work_keys_str_mv | AT dumontelbianca nanotechnologicalengineeringofextracellularvesiclesforthedevelopmentofactivelytargetedhybridnanodevices AT susafrancesca nanotechnologicalengineeringofextracellularvesiclesforthedevelopmentofactivelytargetedhybridnanodevices AT limongitania nanotechnologicalengineeringofextracellularvesiclesforthedevelopmentofactivelytargetedhybridnanodevices AT vighettoveronica nanotechnologicalengineeringofextracellularvesiclesforthedevelopmentofactivelytargetedhybridnanodevices AT debellisdoriana nanotechnologicalengineeringofextracellularvesiclesforthedevelopmentofactivelytargetedhybridnanodevices AT cantamarta nanotechnologicalengineeringofextracellularvesiclesforthedevelopmentofactivelytargetedhybridnanodevices AT caudavalentina nanotechnologicalengineeringofextracellularvesiclesforthedevelopmentofactivelytargetedhybridnanodevices |